It’s exceedingly expensive to own a pet, prompting owners to delay veterinary visits or reconsider adopting one in the first place. Yet, animal health companies’ earnings keep growing.That’s down to the unwavering love between owners and their pets.While some owners might extend the time between their pets’ annual wellness visits to save money, they’ll shell out when their darling is truly sick or hurt, and that care is often the most expensive — and lucrative.Last year, Matthew Joseph, a 41-year-old New Yo ...

Core Insights - Elanco Animal Health Incorporated (ELAN) shares increased by 7.6% to close at $25.18, following a period of 6.9% loss over the past four weeks, indicating a significant turnaround in investor sentiment [1][2] Financial Performance - Elanco reported a modest earnings beat and solid revenue growth in its fourth-quarter performance, reflecting improved operational execution and steady demand across core segments [2] - The company is expected to post quarterly earnings of $0.35 per share, representing a year-over-year decline of 5.4%, while revenues are projected to be $1.28 billion, up 7.7% from the previous year [3] Future Outlook - Management provided constructive guidance for 2026, anticipating continued revenue growth and stronger EBITDA expansion, supported by margin improvement initiatives and cost efficiencies, which signals a clearer path to sustained profitability [2] - The consensus EPS estimate for the upcoming quarter has been revised 1.8% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Industry Context - Elanco operates within the Zacks Medical - Outpatient and Home Healthcare industry, where it holds a Zacks Rank of 3 (Hold) [5] - Quest Diagnostics (DGX), another company in the same industry, has also experienced a decline, with a 0.2% drop in its stock price and a return of -3.8% over the past month [5][6]

Elanco Animal Health Inc. (NYSE:ELAN) is one of the 10 Stocks That Made Millionaires Today. Elanco Animal Health rallied for a third consecutive day on Tuesday, jumping 7.61 percent to finish at $25.18 apiece, as investors took heart from its upbeat outlook for the year, to be supported by plans to leverage AI. At the 2026 KeyBanc Capital Markets Healthcare Forum on the same day, Elanco Animal Health Inc. (NYSE:ELAN) Chief Finance Officer Robert VanHimbergen outlined the company’s growth strategy for th ...

Core Viewpoint - Ten stocks showed strong performance on Tuesday, reflecting a broader market rally driven by positive company outlooks and analyst upgrades [1] Group 1: Stock Performances - Elanco Animal Health Inc. (NYSE:ELAN) increased by 7.61% to $25.18, supported by an optimistic outlook leveraging AI, aiming for 4-6% organic revenue growth and 8% adjusted EBITDA growth [4][5] - BrightSpring Health Services Inc. (NASDAQ:BTSG) rose by 7.81% to $42.10, maintaining a revenue growth guidance of 11.9% to 16.2%, with pharmacy revenues expected to grow by 10.1% to 14.5% [7][8] - Red Cat Holdings Inc. (NASDAQ:RCAT) bounced back by 9.20% to $16.97, anticipating a revenue surge of 1,800% in Q4 and 153% for the full year [11][12] - Western Digital Corp. (NASDAQ:WDC) climbed 9.64% to $313.81, reporting a 296% increase in diluted net income to $1.8 billion and a 25% revenue increase to $3.02 billion [14][15] - Planet Labs PBC (NYSE:PL) saw a 10.08% increase to $27.08, with full fiscal year revenue growth expected between $297 million and $301 million, reflecting a 21.5% to 23% year-on-year growth [17][18] Group 2: Financial Highlights - Elanco's revenues increased by 6% to $4.7 billion, despite a net loss of $232 million, with Q4 revenues up 12% to $1.144 billion [6] - BrightSpring's net income improved to $104.8 million from a net loss of $68.9 million, with revenues up 28.2% to $12.9 billion [9][10] - Red Cat's Q4 revenues are projected to be between $24 million and $26.5 million, a significant increase from $1.3 million in the same period last year [12] - Western Digital's revenues for the upcoming third quarter are targeted at $3.2 billion, with diluted earnings per share expected at $2.30 [16] - Planet Labs anticipates Q4 revenues of $76 million to $80 million, with a projected negative adjusted EBITDA of $5 million to $7 million [19]

Core Insights - The company experienced strong growth in key products, particularly Zenrelia and Credelio Quattro, closing the fourth quarter with significant momentum [1] Financial Performance - The company reported revenues of $892 million from its basket of innovation, surpassing expectations and guidance of $840 to $880 million for the year [2] - The revenue forecast for the basket of innovation has been raised from $1.1 billion to $1.15 billion for 2026, reflecting the positive momentum observed through December [2]

Summary of Elanco Animal Health Conference Call Company Overview - **Company**: Elanco Animal Health - **Industry**: Animal Health Key Points Financial Performance - Elanco reported revenues of **$892 million** from its basket of innovation, exceeding the guidance of **$840-$880 million** for the year [2][3] - The revenue guidance for 2026 has been raised to **$1.15 billion** due to strong momentum [3] - The company expects **4%-6% organic constant currency growth**, **8% adjusted EBITDA growth**, and **10% adjusted EPS growth** for 2026 [10][11] Product Performance - **Credelio Quattro** and **Zenrelia** are key products driving growth, with Quattro being positioned as the best medicine in the parasiticides market, which is valued at **$1 billion** and growing at **30%** [3][4] - Zenrelia has achieved a **double-digit market share** in the U.S. and has expanded to **3,500 clinics** following a label update [4][21] - **Experior**, another product, generated revenues exceeding **$200 million** in 2025, growing **80%** in a total addressable market of **$350 million** [5][6] Market Dynamics - The company is monitoring the impact of geopolitical events, such as the conflict in Iran, but currently does not see a material impact on costs or supply chain [8] - The willingness to spend on pet health is increasing, with **one-third** of pet owners spending more on their pets' health than their own [33] Innovation and R&D - Elanco is focused on expanding its product pipeline, with over **10 potential blockbuster products** expected in the next decade [15][16] - The company is investing in **AI and automation** to enhance efficiency across various functions, including R&D and manufacturing [45][46] Strategic Initiatives - Elanco plans to continue pursuing **M&A** to enhance R&D capabilities while maintaining a focus on deleveraging [40][41] - The company is also expanding its geographic reach, with approvals for Quattro in Australia and submissions in Canada, the EU, UK, and Japan [27][28] Future Outlook - The company anticipates that the globalization of its products will be a key driver for long-term growth, with significant potential in international markets [28] - The launch of **Befrena** is expected in mid-2026, with a phased rollout planned [25][26] Operational Efficiency - Elanco Ascend is expected to contribute **$200 million-$250 million** in net EBIT improvement by 2030, with a focus on gross margin enhancement [55][56] - The company aims to achieve **$25 million** in savings this year from restructuring efforts, with a total expected benefit of **$60 million** by 2027 [57] Additional Insights - The competitive landscape is being closely monitored, with potential impacts from foreign exchange rates and competitive responses to Elanco's product success [12][13] - The company emphasizes the importance of a comprehensive portfolio to meet the evolving needs of pet owners [36][37]

Core Insights - Elanco is experiencing significant momentum, ending Q4 with strong performance that exceeded guidance across revenue, earnings, and cash flow metrics [2] - The company reported $892 million in revenue from its innovation basket, surpassing previous guidance, and has raised expectations for this segment to $1.150 billion by 2026 [2] Financial Performance - Elanco's Q4 results showed a strong finish, with revenue and earnings beating expectations [2] - Cash flow performance was notably strong, allowing the company to reduce leverage more than anticipated [2] Future Outlook - The company provided guidance for 2026, projecting mid-single-digit top line growth and high single-digit EBITDA growth, consistent with previous forecasts made during the Investor Day in December [3]

Elanco Animal Health Conference Call Summary Company Overview - **Company**: Elanco Animal Health (NYSE: ELAN) - **Date**: March 11, 2026 - **Key Speakers**: CFO Bob VanHimbergen, U.S. Business Head Bobby Modi Key Points Financial Performance - Elanco ended Q4 with strong performance, exceeding guidance on revenue, earnings, and cash flow, resulting in a reduction of debt levels [2][3] - Revenue from innovation basket reached **$892 million**, with expectations raised to **$1.15 billion** for 2026 [3] - Projected growth rates for 2026 include mid-single-digit top-line growth, high single-digit EBITDA growth, and low double-digit EPS growth [3] Product Innovations - **Credelio Quattro**: - Achieved a **40% market share** in the endectocide space, with significant growth potential as it is currently in only **1/3 of U.S. clinics** [4][5] - Approximately **35%** of Quattro's volume comes from new starts, indicating strong brand loyalty among new puppies [5] - **Zenrelia**: - Momentum increased in Q3 and Q4 of 2025, with **3,500 clinics** signed on, now present in over **50% of U.S. clinics** [8][9] - Ongoing collaboration with the FDA for label updates, which could enhance market share further [9][10] - **Befrena**: - Anticipated strong demand with **83%** of veterinarians indicating they would adopt the product [14] - Positioned to leverage existing clinics that already use Zenrelia for faster adoption [14][15] Market Dynamics - Elanco's corporate partnerships are gradually increasing, with **90%** of corporate partners seeing net sales growth in 2025, up from **13%** in 2024 [22] - The U.S. farm business grew **17%** in Q4, driven by strong performance from Experior, which has surpassed **$200 million** in annual revenue [29][25] - Favorable cattle market conditions are expected to continue, supported by high beef prices and favorable producer economics [30][32] Cost Management and Efficiency - Elanco Ascend program aims for **$250 million** EBIT improvement, with **$25 million** expected in 2026 from restructuring actions [37] - Anticipated **40 basis points** gross margin improvement in 2026, with further enhancements expected over the next several years [38] Strategic Focus - Continued emphasis on organic growth and debt reduction, with plans to reach leverage below **3 times** by 2027 [59] - Small tuck-under M&A opportunities will be pursued, focusing on enhancing R&D capabilities without derailing deleveraging efforts [60][61] Investor Insights - The pharmaceutical business is viewed as underappreciated, with efficient EBITDA margins comparable to the pet side [62] - The innovation pipeline is expected to drive growth across all business segments, with a focus on differentiated products in established markets [63] Conclusion - Elanco is positioned for growth through its innovative product pipeline, strong market presence, and strategic focus on efficiency and corporate partnerships. The company aims to leverage its strengths in both the pet and farm sectors to enhance shareholder value and drive long-term growth.

Core Insights - Elanco is represented by Bob VanHimbergen, the Chief Financial Officer, and Bobby Modi, Head of U.S. Pet Health and Global Digital Transformation, at a recent event [1][2] Group 1 - The event took place in Miami, indicating a strategic location for engaging with stakeholders [2] - The presence of key executives suggests a focus on transparency and communication with investors [1][2]

Elanco Animal Health FY Conference Summary Company Overview - **Company**: Elanco Animal Health (NYSE: ELAN) - **Date of Conference**: March 10, 2026 - **Key Speakers**: Bob VanHimbergen (CFO), Bobby Modi (Head of U.S. Pet Health and Global Digital Transformation) Key Points Financial Performance - **Q4 2025 Performance**: - Revenue growth of 9% organically - U.S. Pet Health business grew by 10% - U.S. farm business grew by 17% - International business also performed well with 9 countries showing growth and all top 5 franchises increasing sales [6][19] - **2026 Guidance**: - Mid-single-digit top-line growth - High single-digit EBITDA growth - Low double-digit EPS growth - Deleveraging target to below 3 times by 2027 [6][55] Innovation and Product Launches - **Innovation Basket**: - Contributed over $400 million in growth year-over-year - Expected to grow by an additional $250 million in 2026 [22][55] - **New Product Launches**: - Launched 12 differentiated assets in the last 3 years, contributing to market share growth [10] - Quattro and Zenrelia are highlighted as key products driving growth [28][46] Market Dynamics - **U.S. Pet Health**: - Strong growth driven by new product launches and increased market share in various categories including pain, vaccines, and parasiticides [10][28] - Combo products are growing rapidly, with 30% growth in the category and two-thirds of puppies starting on combo products [33][34] - **Farm Business**: - Grew 17% in Q4, led by cattle and poultry, with the Experior product crossing $200 million in revenue [19][20] - International farm business grew by 4%, driven by global protein demand [21] Pricing Strategy - **Pricing Dynamics**: - 2% price increase in 2025 with 5% volume growth - Expecting acceleration in pricing for 2026 [15][16] - **Market Positioning**: - Focus on value-based pricing and maintaining a balance between volume and pricing [15][16] Competitive Landscape - **Zenrelia's Market Position**: - Gained significant market share in Brazil (40%) and Japan (30%) [21][37] - Anticipated to perform well against new competitors due to its efficacy and established market presence [46] Future Outlook - **Long-term Growth**: - Industry expected to grow by $20 billion over the next decade, with opportunities in both pet and farm segments [62] - Continued investment in R&D to ensure a robust pipeline of new products [51][65] - **Margin Improvement**: - Expected net EBITDA improvement of $200-$250 million by 2030 through operational efficiencies and cost management [58][59] Additional Insights - **Consumer Trends**: - Increased willingness to spend on pet care, supporting growth in the animal health market [62][65] - **Omni-channel Strategy**: - Focus on providing products through various channels to meet consumer preferences [64][65] This summary encapsulates the key insights and financial performance of Elanco Animal Health as discussed in the FY conference, highlighting growth drivers, market dynamics, and future outlook.